Literature DB >> 25911238

Sample conditions determine the ability of thrombin generation parameters to identify bleeding phenotype in FXI deficiency.

Gillian N Pike1, Anthony M Cumming2, Charles R M Hay1, Paula H B Bolton-Maggs3, John Burthem1.   

Abstract

Individuals with Factor XI (FXI) deficiency have a variable bleeding tendency that does not correlate with FXI:C levels or genotype. Comparing a range of sample conditions, we tested whether the thrombin generation assay (TGA) could discriminate between control subjects (n = 50) and FXI-deficient individuals (n = 97), and between those with bleeding tendency (n = 50) and without (n = 24). The comparison used platelet-rich plasma (PRP) and platelet-poor plasma (PPP), either with or without corn trypsin inhibitor (CTI) to prevent contact activation, over a range of tissue factor (TF) concentrations. When contact activation was inhibited and platelets were absent, FXI:C levels did not correlate with thrombin generation parameters, and control and FXI-deficient individuals were not distinguished. In all other sample types, the best discrimination was obtained using TF 0.5 pM and assay measures: endogenous thrombin potential (ETP) and peak height. We showed that although a number of conditions could distinguish differences between the groups tested, TGA measured in PRP with CTI best differentiated between bleeders and nonbleeders. These measures provided high sensitivity and specificity (peak height receiver operating characteristic [ROC] area under the curve [AUC] = 0.9362; P < .0001) (ETP ROC AUC = 0.9362; P < .0001). We conclude that by using sample conditions directed to test specific pathways of FXI activation, the TGA can identify bleeding phenotype in FXI deficiency.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25911238     DOI: 10.1182/blood-2014-12-616565

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Differential roles of factors IX and XI in murine placenta and hemostasis under conditions of low tissue factor.

Authors:  Steven P Grover; Clare M Schmedes; Alyson C Auriemma; Emily Butler; Molly L Parrish; Adam Miszta; Audrey C Cleuren; Mayken Visser; Stefan Heitmeier; Jens J Posma; Henri M Spronk; Silvio Antoniak; Alisa S Wolberg; Rafal Pawlinski; David Gailani; Nigel Mackman
Journal:  Blood Adv       Date:  2020-01-14

2.  Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH.

Authors:  Y Dargaud; A S Wolberg; E Gray; C Negrier; H C Hemker
Journal:  J Thromb Haemost       Date:  2017-06-28       Impact factor: 5.824

3.  Molecular genetic analysis of the F11 gene in 14 Turkish patients with factor XI deficiency: identification of novel and recurrent mutations and their inheritance within families.

Authors:  Seyma Colakoglu; Turan Bayhan; Betül Tavil; Ebru Yılmaz Keskin; Volkan Cakir; Fatma Gümrük; Mualla Çetin; Selin Aytaç; Ergul Berber
Journal:  Blood Transfus       Date:  2016-10-04       Impact factor: 3.443

Review 4.  The hemostatic role of factor XI.

Authors:  Cristina Puy; Rachel A Rigg; Owen J T McCarty
Journal:  Thromb Res       Date:  2016-05       Impact factor: 3.944

5.  Abnormal plasma clot formation and fibrinolysis reveal bleeding tendency in patients with partial factor XI deficiency.

Authors:  Gillian N Gidley; Lori A Holle; John Burthem; Paula H B Bolton-Maggs; Feng-Chang Lin; Alisa S Wolberg
Journal:  Blood Adv       Date:  2018-05-22

Review 6.  Why factor XI deficiency is a clinical concern.

Authors:  Allison P Wheeler; David Gailani
Journal:  Expert Rev Hematol       Date:  2016-06-24       Impact factor: 2.929

7.  Why patients with THBD c.1611C>A (p.Cys537X) nonsense mutation have high levels of soluble thrombomodulin?

Authors:  Yohann Jourdy; Nathalie Enjolras; Sandra Le Quellec; Jean Claude Bordet; Claude Négrier; Christine Vinciguerra; Yesim Dargaud
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

8.  Platelet-Derived Short-Chain Polyphosphates Enhance the Inactivation of Tissue Factor Pathway Inhibitor by Activated Coagulation Factor XI.

Authors:  Cristina Puy; Erik I Tucker; Ivan S Ivanov; David Gailani; Stephanie A Smith; James H Morrissey; András Gruber; Owen J T McCarty
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

9.  Role of platelets in regulating activated coagulation factor XI activity.

Authors:  Stéphanie E Reitsma; Jiaqing Pang; Vikram Raghunathan; Joseph J Shatzel; Christina U Lorentz; Erik I Tucker; András Gruber; David Gailani; Owen J T McCarty; Cristina Puy
Journal:  Am J Physiol Cell Physiol       Date:  2021-01-20       Impact factor: 4.249

10.  Prochemerin cleavage by factor XIa links coagulation and inflammation.

Authors:  Xiaomei Ge; Yasuto Yamaguchi; Lei Zhao; Loredana Bury; Paolo Gresele; Caroline Berube; Lawrence L Leung; John Morser
Journal:  Blood       Date:  2017-11-20       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.